ArticleMedicine2026
Global, regional, and national burden of chronic hepatitis C including cirrhosis from 1990 to 2021, alongside projections for the next 15 years.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis C (CHC), including cirrhosis, remains a major global health challenge. While direct-acting antivirals have improved prognoses, barriers to diagnosis and equitable access hinder World Health Organization's 2030 eradication target. This study systematically assessed the global burden and trends to inform prevention strategies. Based on the Global Burden of Disease Study 2021 database, this analysis quantified the absolute numbers and age-standardized rates (ASRs) of 4 disease burden indicators, including incidence, prevalence, deaths, and disability-adjusted life years (DALYs), for CHC, including cirrhosis, across global, regional, and national levels from 1990 to 2021. Temporal trends were quantified using the estimated annual percent change and Joinpoint regression. Decomposition, health inequality, and frontier analyses were used to characterize drivers and socioeconomic gradients, with Bayesian age-period-cohort projections to 2036. Analyses were stratified by socio-demographic index (SDI), sex, and age. In 2021, the global numbers of incidence, prevalence, deaths, and DALYs for CHC, including cirrhosis, were substantially higher than in 1990, though the ASRs declined. Significant socioeconomic inequalities persisted, with the highest burden in low SDI regions. South Asia, Southeast Asia, East Asia, Western Sub-Saharan Africa, and North Africa and the Middle East showed the highest absolute numbers for disease burden indicators; Sub-Saharan Africa, Central Asia, Southeast Asia, and North Africa and the Middle East had the highest ASRs. Males exhibited higher deaths and DALYs than females. Decomposition analysis identified population growth and aging as drivers of increased disease burden, partially countered by epidemiological improvements. Frontier analysis revealed substantial unrealized potential in low SDI settings. Projections indicated a continued decline in ASRs, but the number of prevalence may reach approximately 150 million by 2036 under the continuation of current trends. Despite declining ASRs of CHC, including cirrhosis, from 1990 to 2021, the absolute burden increased due to demographic shifts. Pronounced socioeconomic inequalities persist, with the highest burden concentrated in low SDI regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.